Thursday, 5 November 2026European Markets

VOLTALIA Stock Went Down By Over 13% At Session Start Today

Loading stream...

(vianews) - shares of voltalia (cac 40: vltsa.pa) slid by a staggering 13.03% to €13.48 at 10:09 est on thursday, after three successive sessions in a row of losses. cac 40 is falling 0.2% to €7,116.57, after three sequential sessions in a row of gains. this seems, so far, a somewhat down trend trading session today.

about voltalia

voltalia sa engages in the production of electricity from renewable energy sources. it operates through two segments, energy sales and services. the company develops, constructs, operates, and maintains wind, solar, hydro, and biomass power plants. it also develops and sells projects, and procures equipment for solar power plants, as well as provides maintenance service. as of december 31, 2021, the company operated solar power plant with an installed capacity of 98 mw. it operates in africa, the middle east, asia, other europe, brazil, and latin america. the company was incorporated in 2005 and is headquartered in paris, france. voltalia sa is a subsidiary of voltalia investissement sa.

earnings per share

as for profitability, voltalia has a trailing twelve months eps of €0.08.

pe ratio

voltalia has a trailing twelve months price to earnings ratio of 162.41. meaning, the purchaser of the share is investing €162.41 for every euro of annual earnings.

volatility

voltalia's last week, last month's, and last quarter's current intraday variation average was a negative 2.87%, a negative 0.65%, and a positive 1.38%.

voltalia's highest amplitude of average volatility was 2.87% (last week), 1.64% (last month), and 1.38% (last quarter).

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, voltalia's stock is considered to be overbought (>=80).

volume

today's last reported volume for voltalia is 138197 which is 204.86% above its average volume of 45330.

more news about voltalia (vltsa.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com